《大行報告》匯豐研究上調保利協鑫(03800.HK)目標價至4元 維持「買入」評級
匯豐研究發表研究報告指出,該行最近到訪保利協鑫(03800.HK)位於江蘇的顆粒狀多晶矽新生產線,該生產線於兩周前才投產。雖然部分投資者對公司的顆粒狀多晶矽抱懷疑態度,但相信未來數周公司將吸引更多的投資者參觀該工廠,有助提高更多透明度。
該行指出,保利協鑫樂山工廠可作為公司2022財年中期的一個重要里程碑,因估計其有助於解決市場對公司可擴展性、質量和成本的憂慮。此外,該行對公司的預測不變,但目標價由3.4元上調至4元,維持「買入」評級,認為公司粒狀聚合物的進一步突破,可能為公司提供明顯超越同行的優勢,尤其是在市場下行周期的情況下。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.